Literature DB >> 26834096

¹⁸F-FDG PET/CT for Staging and Restaging of Breast Cancer.

David Groheux1, Alexandre Cochet2, Olivier Humbert2, Jean-Louis Alberini3, Elif Hindié4, David Mankoff5.   

Abstract

Many studies have pointed out the role of (18)F-FDG PET/CT (or (18)F-FDG PET) in patients with clinical stage III or II breast cancer. (18)F-FDG PET/CT might advantageously replace other staging procedures, such as bone scanning and possibly contrast-enhanced CT of the thorax or abdomen-pelvis. We discuss the findings, locoregional or distant, that can be expected in different categories of breast cancer and their impact on prognosis and management. We also discuss the role of (18)F-FDG PET/CT in restaging and how (18)F-FDG PET/CT compares with conventional techniques in restaging for patients with suspected disease recurrence. We conclude with some recommendations for clinical practice and future research.
© 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  18F-FDG PET/CT; breast cancer; prognosis; restaging; staging

Mesh:

Substances:

Year:  2016        PMID: 26834096     DOI: 10.2967/jnumed.115.157859

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  44 in total

1.  Prediction of breast cancer recurrence using lymph node metabolic and volumetric parameters from 18F-FDG PET/CT in operable triple-negative breast cancer.

Authors:  Yong-Il Kim; Yong Joong Kim; Jin Chul Paeng; Gi Jeong Cheon; Dong Soo Lee; June-Key Chung; Keon Wook Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06-14       Impact factor: 9.236

2.  FDG-PET/CT for systemic staging of patients with newly diagnosed breast cancer.

Authors:  David Groheux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08       Impact factor: 9.236

3.  Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients.

Authors:  Charles Lemarignier; Antoine Martineau; Luis Teixeira; Laetitia Vercellino; Marc Espié; Pascal Merlet; David Groheux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-02-10       Impact factor: 9.236

4.  Is (18)FDG uptake useful to decide on chemotherapy in ER+/HER2- breast cancer?

Authors:  David Groheux; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08       Impact factor: 9.236

5.  PET-CT for Evaluating Breast Cancer Yields Incidental Finding in the Lung.

Authors:  Raquel Perez; Gladys Montane; Jill S Gluskin; Garth Nanni
Journal:  Radiol Technol       Date:  2019-11

6.  Unusual Horner's Syndrome in Recurrent Breast Cancer: Evaluation Using 18F-FDG PET/CT.

Authors:  Sohyun Park; Tae Sung Kim; Seok-Ki Kim
Journal:  Nucl Med Mol Imaging       Date:  2016-08-01

7.  Hybrid PET/MRI in major cancers: a scoping review.

Authors:  Anni Morsing; Malene Grubbe Hildebrandt; Mie Holm Vilstrup; Sara Elisabeth Wallenius; Oke Gerke; Henrik Petersen; Allan Johansen; Thomas Lund Andersen; Poul Flemming Høilund-Carlsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-07-02       Impact factor: 9.236

8.  Unusual Contralateral Axillary Lymph Node Metastasis in a Second Primary Breast Cancer Detected by FDG PET/CT and Lymphoscintigraphy.

Authors:  Ji-Young Kim; Hyunjong Lee; Tae Sung Kim; Han-Sung Kang; Seok-Ki Kim
Journal:  Nucl Med Mol Imaging       Date:  2017-08-11

9.  The value of 18F-FDG PET/CT imaging in breast cancer staging.

Authors:  Ulkem Yararbas; Neslihan Cetin Avci; Levent Yeniay; Aziz Murat Argon
Journal:  Bosn J Basic Med Sci       Date:  2018-02-20       Impact factor: 3.363

10.  PET Imaging of L-Type Amino Acid Transporter (LAT1) and Cystine-Glutamate Antiporter (xc-) with [18F]FDOPA and [18F]FSPG in Breast Cancer Models.

Authors:  Daniel Krys; Stephanie Mattingly; Darryl Glubrecht; Melinda Wuest; Frank Wuest
Journal:  Mol Imaging Biol       Date:  2020-08-13       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.